These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 16510173

  • 1. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
    Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.
    Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173
    [Abstract] [Full Text] [Related]

  • 2. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
    Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.
    Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP.
    Cancer Res; 2003 Feb 15; 63(4):807-11. PubMed ID: 12591730
    [Abstract] [Full Text] [Related]

  • 6. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
    Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brännström M.
    Gynecol Oncol; 1998 Dec 15; 71(3):420-3. PubMed ID: 9887242
    [Abstract] [Full Text] [Related]

  • 7. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D.
    J BUON; 2007 Dec 15; 12(1):99-104. PubMed ID: 17436409
    [Abstract] [Full Text] [Related]

  • 8. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.
    Cancer Epidemiol Biomarkers Prev; 2009 Apr 15; 18(4):1127-33. PubMed ID: 19336561
    [Abstract] [Full Text] [Related]

  • 9. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
    Wu L, Sun J, Wang X.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Feb 15; 33(2):92-4. PubMed ID: 10682428
    [Abstract] [Full Text] [Related]

  • 10. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C.
    Gynecol Oncol; 2009 May 15; 113(2):221-7. PubMed ID: 19261323
    [Abstract] [Full Text] [Related]

  • 11. Serum C-reactive protein in the differential diagnosis of ovarian masses.
    Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, Tempfer CB.
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov 15; 147(1):65-8. PubMed ID: 19619929
    [Abstract] [Full Text] [Related]

  • 12. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD, Gamboa G, Kurosaki T, Buller R, Walker JL, Manetta A.
    Gynecol Oncol; 1997 Jul 15; 66(1):71-4. PubMed ID: 9234924
    [Abstract] [Full Text] [Related]

  • 13. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Mar 15; 104(3):508-15. PubMed ID: 17113137
    [Abstract] [Full Text] [Related]

  • 14. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L, Tempfer C, Häusler G, Heinzl H, Kainz C.
    Wien Klin Wochenschr; 1998 Oct 02; 110(18):635-41. PubMed ID: 9816636
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP.
    Gynecol Oncol; 2007 Aug 02; 106(2):334-41. PubMed ID: 17498784
    [Abstract] [Full Text] [Related]

  • 17. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H, Duranyildiz D, Tas F, Yasasever V.
    Am J Clin Oncol; 2008 Dec 02; 31(6):585-8. PubMed ID: 19060592
    [Abstract] [Full Text] [Related]

  • 18. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
    Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC.
    Am J Obstet Gynecol; 2008 Apr 02; 198(4):418.e1-7. PubMed ID: 18241816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
    Li L, Wang LM, Zhang W, Zhang JQ, Song HL, Yao DS, Tang Y, Chen XQ, Yang ZH.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb 02; 38(2):72-6. PubMed ID: 12783691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.